Sign inCreate account

Report workspace tools

NCT00286091COMPLETEDanonymous

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Sponsor

Source record

Amgen

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab, Placebo

Indication / condition

AI-normalized

Hormone Refractory Prostate Cancer

Intervention

Source record

Denosumab, Placebo

Source & freshness

Source record

NCT ID

NCT00286091

Original source

ClinicalTrials.gov

Source last updated

Oct 17, 2018

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00286091

Title

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE3

Condition raw

Hormone Refractory Prostate Cancer

Condition normalized

Hormone Refractory Prostate Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Denosumab, Placebo

Target normalized

Denosumab, Placebo

Interventions

Denosumab, Placebo

Public preview

Source record

The purpose of this study is to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormone refractory (androgen independent) prostate cancer who have no bone metastasis at baseline.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00286091

Status

COMPLETED

Phase

PHASE3

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

The purpose of this study is to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormone refractory (androgen independent) prostate cancer who have no bone metastasis at baseline.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 17, 2018
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00286091

Indication

Hormone Refractory Prostate Cancer

Modality

monoclonal antibody

Target

Denosumab, Placebo

Intervention

Denosumab, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.